Neuramis Light (with Lidocaine)
Neuramis
Aesthetic / Medical DeviceHyaluronic Acid Dermal Filler (Superficial / Fine-line correction)
Certifications
- CE marking reported for Neuramis product family in applicable EU/EEA markets (verify specific SKU certificate with manufacturer/distributor)
- Manufactured under medical device quality systems (manufacturer: Medytox)
- CE marking reported for Neuramis product family in applicable EU/EEA markets (verify specific SKU certificate with manufacturer/distributor)
- Manufactured under medical device quality systems (manufacturer: Medytox)
Hyaluronic Acid Dermal Filler (Superficial / Fine-line correction)
Description
Neuramis Light (with Lidocaine) is a low-viscosity, cross-linked hyaluronic acid gel formulated for subtle skin rejuvenation and correction of fine superficial lines. Intended for delicate areas such as under-eyes (tear troughs), perioral lines and lips, the product provides hydration, improved skin texture and mild contouring with minimal discomfort due to included lidocaine. Supplied as a single-use prefilled 1 mL syringe.
Bnefits
- Corrects fine lines and subtly rejuvenates skin surface
- Improves skin hydration and elasticity
- Suitable for delicate areas (under-eyes, perioral lines, lips)
- Includes lidocaine (0.3% w/w) to reduce injection discomfort
- Manufactured using SHAPE™ two-step cross-linking technology for gel stability and prolonged effect
Indications
- Correction of fine superficial lines (periorbital, perioral, forehead fine lines)
- Tear-trough / under-eye rejuvenation (by experienced injectors)
- Lip hydration and mild contouring
- Improvement of skin texture and superficial dehydration-related lines
Composition
- Cross-linked Hyaluronic Acid (HA) — 20 mg/mL
- Lidocaine (as hydrochloride) — 0.3% w/w (≈3 mg/mL)
- Sterile aqueous gel base and excipients as per manufacturer's IFU
Formulation
Not publicly listed
Packaging
Not publicly listed
Usage
- For professional use only — to be administered by trained medical practitioners experienced in dermal filler injections.
- Select injection depth and technique appropriate for delicate/superficial areas (micro-bolus, serial puncture, micro-droplet techniques).
- Follow aseptic technique and local protocols; tailor volume and placement to individual anatomy.
- Provide standard post-treatment aftercare (avoid intense heat, alcohol, strenuous exercise for 24–48 hours).
- Keep hyaluronidase available to manage rare adverse events requiring filler dissolution.
Contraindications
- Active infection or inflammation at the injection site
- Known hypersensitivity to any component (including lidocaine or HA)
- History of severe allergies or anaphylaxis
- Use in pregnancy or breastfeeding only after clinician risk/benefit assessment
Adverse Effects
- Common (usually transient): injection-site swelling, redness, pain, bruising, itching
- Less common/serious: infection, nodules/granulomas, hypersensitivity reactions, vascular occlusion (rare; can cause tissue necrosis or visual complications if not promptly treated)
- Potential systemic lidocaine effects are unlikely at intended local doses but possible with inadvertent intravascular administration
Storage Conditions
- Store in original packaging at 2–25°C; do not freeze.
- Protect from excessive heat and direct sunlight.
- Shelf life commonly 24 months from manufacture (verify batch IFU/expiry).
Duration
Typical clinical duration approximately 6\u20139 months for superficial indications; longevity varies by treatment area, patient metabolism and technique.
Onset
Immediate visible correction/rehydration after injection; final settling and tissue integration over several days to two weeks.
